45 years and older
Male or Female
Post-stroke cognitive decline and dementia pose a significant public health problem. The risk of dementia is more than doubled after stroke, and over 2 million American stroke survivors sufferfrom dementia. Silent (or ‘covert’) infarcts are likely an important cause of cognitive decline in stroke survivors, particularly in patients at high risk for cardioembolism. This notion is supported by studies that describe a relationship between atrial fibrillation and incidentdementia, studies demonstrating that patients with cardioembolic stroke are at greatest risk of cognitive decline5, and studies showing that anti-coagulation reduces the occurrence of infarcts and cognitive decline in stroke survivors with atrial fibrillation. The evidence suggesting that silent infarcts caused by cardioembolism plays an important role in the development of post-stroke cognitive decline prompted the design of ARCADIA-CSI, anancillary study to the ARCADIA trial, that will test if treatment with apixaban is an effective strategy to prevent silent infarcts and preserve cognitive function in patients with stroke of unknown cause and atrial cardiopathy.
For further information about this study or to express your interest in this study, please fill out and submit this form.
This setting allows you to view available services and providers associated with your preferred location. You can change this setting at any time.
Cookies are required to view location specific content.
We’ve developed a new tool on our website allowing you to see content most relevant to you and your preferred location. It’s our way of making the information you need, more personalized.
You’ll find this feature labeled “Set My Location” throughout the website. Most often, you’ll see it in the top left corner of every page.
You’ll also find a feature that allows you to set your location temporarily, as seen below.